Eskazan, A. E. Et Al. 2011. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?. LEUKEMIA RESEARCH , vol.35, no.9 .

Eskazan, A. E., Soysal, T., Erbilgin, Y., Ozbek, U., & Ferhanoglu, B., (2011). Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?. LEUKEMIA RESEARCH , vol.35, no.9.

Eskazan, Ahmet Et Al. "Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?," LEUKEMIA RESEARCH , vol.35, no.9, 2011

Eskazan, Ahmet E. Et Al. "Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?." LEUKEMIA RESEARCH , vol.35, no.9, 2011

Eskazan, A. E. Et Al. (2011) . "Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?." LEUKEMIA RESEARCH , vol.35, no.9.

@article{article, author={Ahmet Emre EŞKAZAN Et Al. }, title={Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?}, journal={LEUKEMIA RESEARCH}, year=2011}